- Home
- FENC vs AUTL Comparison
FENC vs AUTL Comparison
Compare FENC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | AUTL |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.8M | 335.4M |
| IPO Year | 2010 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FENC | AUTL |
|---|---|---|
| Price | $10.75 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $17.20 | $8.75 |
| AVG Volume (30 Days) | 122.5K | ★ 2.1M |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $44,642,000.00 | $10,120,000.00 |
| Revenue This Year | $62.55 | $98.68 |
| Revenue Next Year | $42.10 | $28.47 |
| P/E Ratio | $164.92 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $5.65 | $1.18 |
| 52 Week High | $13.25 | $2.58 |
Technical Indicators
Market Signals| Indicator | FENC | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 29.37 |
| Support Level | $9.87 | $1.18 |
| Resistance Level | $11.07 | $1.71 |
| Average True Range (ATR) | 0.67 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 73.17 | 16.30 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.